AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05231421 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Each focus group will consist of 5-10 participants. They will first introduce to each other and be asked to keep information shared during the session private. The moderator will initiate some questions for the group to discuss. Prompt and follow-up questions will be asked. There is no right or wrong answer for each question and no sensitive questions will be asked. The conversations during the focus group discussion will be recorded. The group will be debriefed about the purpose of the study and have a chance to ask any questions about the study if they have. The focus group discussion for each session will last about 60-90 minutes.
Study NCT00862394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP/Formoterol Next DPI
Description: BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)
Study NCT00862394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foster
Description: BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
Study NCT00862394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP/Formoterol Next DPI
Description: BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)
Study NCT00862394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foster
Description: BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
Study NCT04001660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subbrow Blepharoplasty Combined with Double Eyelid Surgery
Description: An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
Study NCT04292379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard procedures and assessments
Study NCT04292379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Bundle
Description: Suicide risk screening tool, mental health assessment tool, follow-up appointment
Study NCT03611036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Upper limbs Strength training; done with dumbbells whose weight corresponds to 60-80% of the maximal voluntary force in abduction measured initially, during 4 weeks
Study NCT02628704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: The fixed dose of selinexor is 60 mg (three 20 mg tablets)
Study NCT02628704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for selinexor)
Description: sugar tablet manufactured to mimic selinexor tablet
Study NCT02628704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carfilzomib
Description: Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.
Study NCT02628704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.
Study NCT02628704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.
Study NCT02628704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.
Study NCT02031627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneumatic compression - 1 hour per day
Description: Pneumatic compression treatment once per day (1 hour)
Study NCT02031627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneumatic compression - 2 hours per day
Description: pneumatic compression treatment twice per day in the AM \& PM (2 hours)
Study NCT03611036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: Upper limbs Endurance training of the ; done with dumbbells whose weight corresponds to 30% of the maximum voluntary force in abduction measured initially, during 4 weeks
Study NCT04494360 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No investigational medicinal product will be administered as a part of this study.
Study NCT02031627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneumatic compression - 4 hours per day
Description: pneumatic compression treatment twice per day consisting of 2 consecutive 1 hour treatments in the AM \& PM (4 hours)
Study NCT03300427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsatran
Description: sacubitril/valsatran 100 or 200 mg BID
Study NCT03300427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: Valsartan 80 or 160 mg BID
Study NCT03300427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to valsartan
Description: placebo to valsartan 80 or 160 BID
Study NCT03300427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to sacubitril/valsartan
Description: placebo to sacubitril/valsartan 100 or 200 mg BID
Study NCT03641521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-led behavioral strategies
Description: Intervention parents participated in an additional 20-25-min segment led by the nutrition educator during which the week's behavioral strategy was introduced. The following six behavioral strategies were introduced (one each week) as a segment of each cooking skills session: 1) have your child help prepare vegetables for meals (Child Help), 2) use a plate that shows the amount of vegetables to include for a meal (My Plate), 3) make vegetables visible and accessible by removing other foods from the dining area during the meal and leaving the vegetables (Make Avail/Visible), 4) serve at least 2 vegetables with the meal (Serve 2), 5) serve vegetables before the meal (Serve First), and 6) use a bigger spoon to serve the vegetables (Big Spoon).
Study NCT00223652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone cognitive behavioral therapy
Description: An initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains.
Study NCT00441012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Modified Process Vaccine
Description: Modified process vaccine HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 \& 12 months of age. Duration of treatment is 11 months.
Study NCT00441012 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: COMVAX™
Description: COMVAX™ HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.
Study NCT00559013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Staple line reinforcement
Description: Placement of reinforcement material on circular anastomotic staple line for prevention of leak during and post surgery.
Study NCT02929368 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICC implantation under fluoroscopy
Description: PICC Catheter implantation
Study NCT02929368 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICC Implantation under Sherlock System
Description: PICC Catheter implantation
Study NCT02727881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squalamine lactate ophthalmic solution, 0.2%
Description: Squalamine lactate ophthalmic solution, 0.2%
Study NCT03557736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training mode
Description: type of exercise training completed for 12 weeks
Study NCT00926991 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention; observation only
Study NCT01432704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colecalciferol
Description: Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
Study NCT01432704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colecalciferol
Description: Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
Study NCT02977039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NDPR diet
Description: nutrient rich plant based diert
Study NCT02977039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USDA healthy eating diet
Description: DASH diet
Study NCT01838655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: Oral dose of 2mg daily for 12 months.
Study NCT02027064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Study NCT03921606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (i-BMI)
Description: A brief MI via WhatsApp/WeChat
Study NCT03921606 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individual face-to-face generic health advice
Description: Individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese). A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs.
Study NCT02218762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol Xinafoate DISKUS
Description: A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler
Study NCT02218762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match DISKUS
Description: A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
Study NCT01696981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening Questionnaire Administration
Description: Undergo questionnaire assessments
Study NCT02218762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS
Description: A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
Study NCT01696981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sigmoidoscopy
Description: Undergo a flexible sigmoidoscopy
Study NCT02218762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match ROTACAPS
Description: A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
Study NCT04185740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CloudUPDRS - Tapping Task
Description: The TTT, consisting of two targets, will be presented on the screen of the smartphone. Participants will be instructed to alternate between the two targets using their index finger for 30 seconds. The task will always be performed with the left hand first and then with the right hand. The touch-sensitive screen of the smartphone will measure the timing of each touch event, its duration, the coordinates on the phone screen and the amount of pressure applied.
Study NCT00904111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm®
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
Study NCT00904111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Patch
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
Study NCT00132522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 273066
Description: dose-escalating study and subjects enrolled in the study may receive a maximum of 6 cycles of the assigned regimen over 18 weeks. Each cycle will be 3 weeks (21 days) with cyclophosphamide on Day 1 and EMD 273066 on Days 2 to 4, followed by 17 days with no experimental pharmaceutical product.~Each cycle, cyclophosphamide at 300 mg/m2 given per institutional guidelines 1 day (22-28 hours) prior to 3 consecutive days of EMD 273066 as a 4-hour IV infusion at 1 of 6 planned dose levels of 0.5, 1, 2, 3, 4, or 6 mg/m2.
Study NCT00470678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT02104141 — intervention group
Intervention type: DEVICE
Intervention: ROIA Interbody Cage with VerteBRIDGE plating
Study NCT02727881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic solution
Description: Placebo Ophthalmic solution
Study NCT02727881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ranibizumab
Description: ranibizumab
Study NCT02727881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: ranibizumab
Study NCT01008982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LimphoStat-B
Description: subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
Study NCT04068649 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo palliative RT
Study NCT04068649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04068649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04068649 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT01794026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion weighted magnetic resonance imaging
Description: for diagnostic purposes, diffusion weighted magnetic resonance imaging in all patients
Study NCT03617757 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: Patients will be invited to have oral glucose tolerance test. 2mL blood will be taken for analysis at 0 minute and 120 minutes.
Study NCT03617757 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HbA1c
Description: 2mL blood will be taken for analysis of HbA1c.
Study NCT03009630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Patients diagnosed with early-stage NSCLC and signing the informed consent will be performed RFA under the guidance of ENB.
Study NCT03009630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENB
Description: ENB will be used to guide bronchoscope into the accurate location of the lesion during RFA.
Study NCT01498731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge home
Description: Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
Study NCT04776837 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observational Cohort
Description: Patients will be followed by collecting clinical data, biospecimens, and quality of life assessment
Study NCT01740635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPIC WheelS Training Program
Description: Subjects will attend an initial assessment/training session and receive a customized home program from their Trainer, which is delivered by way of a portable, interactive computer tablet that can be used for practice in their home or other community venues. After 2 weeks of practice, subjects return for a second 1-hour training session. The Trainer updates their program and they continue practicing at home for another 2 weeks. Subjects will have a caregiver attend all training sessions and supervise their home training. Trainers monitor subject activity remotely and will contact subjects by telephone at the end of weeks 1 and 3 to promote program adherence. Participants in an extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week and document these on a simple calendar-style form provided.
Study NCT01798355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The treatment group is offered cognitive behavior therapy(CBT) by psychologists/psychotherapists. CBT is offered according to a treatment manual and consists of 10- sessions during 12-15 weeks.
Study NCT01798355 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment as usual consist of strategies such as habituation, tell-show-do, premedication with midazolam, nitrous oxide sedation and general anesthesia. All offered by dentists and dental hygienist and/or dental assistants.
Study NCT03783039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SURGICEL Powder
Description: Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Powder, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.
Study NCT03783039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL Original
Description: Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Original, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.
Study NCT03638778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 3 mg
Description: Semaglutide 3 mg will be administered once daily (OD) orally in the morning from day 1 to 5.
Study NCT03638778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 7 mg
Description: Semaglutide 7 mg will be administered OD orally in the morning from day 6 to 10.
Study NCT03638778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B 3 mg
Description: Semaglutide B 3 mg will be administered OD orally in the morning from day 1 to 5.
Study NCT03638778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B 7 mg
Description: Semaglutide B 7 mg will be administered OD orally in the morning from day 6 to 10.
Study NCT03638778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide C 3 mg
Description: Semaglutide C 3 mg will be administered OD orally in the morning from day 1 to 5.
Study NCT03638778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide C 7 mg
Description: Semaglutide C 7 mg will be administered OD orally in the morning from day 6 to 10.
Study NCT03638778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D 3 mg
Description: Semaglutide D 3 mg will be administered OD orally in the morning from day 1 to 5.
Study NCT03638778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D 7 mg
Description: Semaglutide D 7 mg will be administered OD orally in the morning from day 6 to 10.
Study NCT02031458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg IV every 3 weeks
Study NCT01473524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)
Description: OCA was administered orally once daily and provided in tablet form in 2 strengths: 5 mg and 10 mg.
Study NCT00446641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: cilostazol 100mg twice a day for 4 weeks
Study NCT00446641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 1 tablet twice a day matching for cilostazol
Study NCT03949127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: The group who will meet a physiotherapist who will show them strengthening and stretching muscles associated with pelvic tilt.
Study NCT01309373 — intervention group
Intervention type: OTHER
Intervention: Patient assessment
Description: 2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.